Skip to main navigation Skip to search Skip to main content

Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report

  • Firoozeh Sahebi*
  • , Laurent Garderet
  • , Abraham S. Kanate
  • , Diderik-Jan Eikema
  • , Nina Simone Knelange
  • , Omar F. Davila Alvelo
  • , Yener Koc
  • , Didier Blaise
  • , Qaiser Bashir
  • , Jose M. Moraleda
  • , Peter Dreger
  • , James F. Sanchez
  • , Stefan Ciurea
  • , Harry Schouten
  • , Nirav N. Shah
  • , Mareike Verbeekl
  • , Wolf Roesler
  • , Jose L. Diez-Martin
  • , Stefan Schoenland
  • , Anita D'Souza
  • Nicolaus Kroeger, Parameswaran Hari
*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Allogeneic hematopoietic cell transplantation (allo-HCT) using siblings and matched donors has the potential for long-term disease control in a subset of high-risk patients with multiple myeloma (MM); however, the data on using haploidentical donors in this disease are limited. We conducted a retrospective analysis to examine the outcomes of patients with MM who underwent haploidentical allo-HCT within European Society for Blood and Marrow Transplantation/Center for International Blood and Marrow Transplant Research centers. A total of 96 patients underwent haploidentical allo-HCT between 2008 and 2016. With a median follow-up of 24.0 months (range, 13.2 to 24.9 months), 97% (95% confidence interval [CI], 93% to 100%) of patients had neutrophil engraftment by day 28, and 75% (95% CI, 66% to 84%) achieved platelet recovery by day 60. Two-year progression -free survival (PFS) was 17% (95% CI, 8% to 26%), and overall survival (OS) was 48% (95% CI, 36% to 59%). At 2 years, the cumulative risk of relapse/progression was 56% (95% CI, 45% to 67%), and 1-year nonrelapse mortality (NRM) was 21% (95% Cl, 13% to 29%). The incidences of acute graft-versus-host-disease (GVHD) grades ll-IV by 100 days and chronic GVHD at 2 years were 39% (95% CI, 28% to 49%) and 46% (95% CI, 34% to 59%), respectively. On univariate analysis, use of post-transplantation cyclophosphamide (PT-Cy) (54% [95% CI, 41% to 68%] versus 25% [95% CI, 1% to 48%]; P=.009) and use of bone marrow as source of stem cells (72% [95% CI, 55% to 89%] versus 31% [95% CI, 17% to 46%]; P=.001) were associated with improved OS at 2 years. Disease status, patient sex, intensity of conditioning regimen, recipient/donor sex mismatch, and cytomegalovirus serostatus had no impact on OS, PFS, or NRM. Haploidentical transplantation is feasible for patients with multiply relapsed or high-risk MM, with an encouraging 2-year OS of 48% and an NRM of 21% at 1 year, supporting further investigation of haploidentical allo-HCT in suitable candidates with MM. (C) 2018 American Society for Blood and Marrow Transplantation.

Original languageEnglish
Pages (from-to)335-342
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume25
Issue number2
DOIs
Publication statusPublished - Feb 2019

Keywords

  • Multiple myeloma
  • Haploidentical
  • Allogeneic hematopoietic cell transplantation
  • STEM-CELL TRANSPLANTATION
  • TANDEM AUTOLOGOUS TRANSPLANTATION
  • EUROPEAN-SOCIETY
  • MARROW
  • BLOOD
  • DONOR
  • LEUKEMIA

Fingerprint

Dive into the research topics of 'Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report'. Together they form a unique fingerprint.

Cite this